Advertisement

Pharmacological Intervention

  • Mina K. Dulcan

Abstract

This chapter will cover psychopharmacology (i.e., the use of psychoactive medications or psychotropic drugs to treat disorders of emotions and behavior in children and adolescents). Medications are commonly called drugs. It is important to distinguish therapeutic drugs from street drugs, or abused substances. Following a section on general principles, each class or group of medications has its own section, with a description, indications for use, efficacy (evidence that the drug works), risks and side effects, and how the drug is generally used. Medications are commonly classified by one of their uses (e.g., antidepressant), a description of their pharmacologic activity (e.g., stimulant or antihistamine), or their chemical structure (e.g., benzodiazepine or lithium). This chapter will not cover doses of medicine. (For more details, see section under Additional Reading.)

Keywords

Adolescent Psychiatry Stimulant Medication Neuroleptic Malignant Syndrome Autistic Disorder Logical Intervention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baren, M., (1989). The case for Ritalin: A fresh look at the controversy. Contemporary Pediatrics, 6, 16–28.Google Scholar
  2. Barkley, R. A., Conners, C. K., Barclay, A., Gadow, K., Gittelman, R., Sprague, R., & Swanson, J. (1990). Task force report: The appropriate role of clinical child psychologists in the prescribing of psychoactive medication for children. Journal of Clinical Child Psychology, 19, (Suppl.) 1–38.Google Scholar
  3. Barkley, R., DuPaul, G., & McMurray, M. (1990). A comprehensive evaluation of Attention Deficit Disorder with and without Hyperactivity as defined by research criteria. Journal of Consulting and Clinical Psychology, 58, 775–789.PubMedCrossRefGoogle Scholar
  4. Biederman, J. (1987). Clonazepam in the treatment of prepubertal children with panic-like symptoms. Journal of Clinical Psychiatry, 48, (Suppl.), 38–41.PubMedGoogle Scholar
  5. Biederman, J., Baldessarini, R. J., Wright, V., Knee, D., & Harmatz, J. S. (1989). A double-blind placebo controlled study of desipramine in the treatment of ADD: I Efficacy. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 777–784.PubMedCrossRefGoogle Scholar
  6. Birmaher, B., Baker, R., Kapur, S., Quintana, H., & Ganguli, R. (1992). Clozapine for the treatment of adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 160–164.PubMedCrossRefGoogle Scholar
  7. Campbell, M., Small, A. M., Green, W. H., Jennings, S. J., Perry, R., Bennett, W. G., & Anderson, L. (1984). Behavioral efficacy of haloperidol and lithium carbonate. Archives of General Psychiatry, 41, 650–656.PubMedCrossRefGoogle Scholar
  8. Campbell, M., Green, W. H., & Deutsch, S. I. (1985). Child and adolescent psychopharmacology. Beverly Hills: Sage Publications.Google Scholar
  9. Campbell, M., Silva, R. R., Kafantaris, V., Locascio, J. J., Gonzalez, N. M., Lee, D., & Lynch, N. S. (1991). Predictors of side effects associated with lithium administration in children. Psychopharmacology Bulletin, 27, 373–380.PubMedGoogle Scholar
  10. Casat, C. D., Pleasants, D. Z., Schroeder, D. H., & Parier, D. W. (1989). Bupropion in children with attention deficit disorder. Psychopharmacology Bulletin, 25, 198–201.PubMedGoogle Scholar
  11. Deveaugh-Geiss, J., Moroz, G., Biederman, J., Cantwell, D., Fontaine, R., Greist, J. H., Reichler, R., Katz, R., & Landau, P. (1992). Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder—a multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 45–49.PubMedCrossRefGoogle Scholar
  12. Donnelly, M., & Rapoport, J. L. (1985). Attention deficit disorders. In J. M. Wiener (Ed.), Diagnosis and psychopharmacology of childhood and adolescent disorders (pp. 178–197). New York: John Wiley & Sons.Google Scholar
  13. Elia, J., Borcherding, B. G., Rapoport, J. L., & Keysor, C. S. (1991). Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders? Psychiatry Research, 36, 141–155.PubMedCrossRefGoogle Scholar
  14. Evans, R. W., Clay, T. H., & Gualtieri, C. T. (1987). Carbamazepine in pediatric psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 2–8.PubMedCrossRefGoogle Scholar
  15. Fritz, G. K., & Rockney, R. (1991). Plasma levels and efficacy of Imipramine treatment for enuresis. Paper presented at the annual meeting of the American Academy of Child and Adolescent Psychiatry.Google Scholar
  16. Ghaziuddin, M., Tsai, L., & Ghaziuddin, N. (1991). An open trial of Clonidine in autism. Paper presented at the annual meeting of the American Academy of Child and Adolescent Psychiatry.Google Scholar
  17. Gordon, C. T., Rapoport, J. L., Hamburger, S. D., State, R. C., & Mannheim, G. B. (1992). Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry, 149, 363–366.PubMedGoogle Scholar
  18. Grob, C. S., Coyle, J. T. (1986). Suspected adverse methylphenidate-imipramine interactions in children. Journal of Developmental and Behavioral Pediatrics, 7, 265–267.PubMedCrossRefGoogle Scholar
  19. Handen, B. L., Feldman, H., Gosling, A., Breaux, A. M., & McAuliffe, S. (1991). Adverse side effects of methylphenidate among mentally retarded children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 241–245.PubMedCrossRefGoogle Scholar
  20. Herskowitz, J. (1987). Developmental neurotoxicology. In C. Popper (Ed.), Psychiatric pharmacosciences of children and adolescents (pp. 81–123). Washington, DC: American Psychiatric Press, Inc.Google Scholar
  21. Hunt, R. D. (1987). Treatment effects of oral and transdermal Clonidine in relation to methylphenidate— an open pilot study in ADHD. Psychopharmacology Bulletin, 23, 111–114.PubMedGoogle Scholar
  22. Hunt, R. D., Capper, L., & O’Connell, P. (1990). Clonidine in child and adolescent psychiatry. Journal of Child and Adolescent Psychopharmacology, 1, 87–102.PubMedCrossRefGoogle Scholar
  23. Klein, R. G., Koplewicz, H. S., & Kanner, A. (1992). Imipramine treatment of children with separation anxiety disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 21–28.PubMedCrossRefGoogle Scholar
  24. Klorman, R., Brumaghim, J. T., Fitzpatrick, P. A., & Borgstedt, A. D. (1990). Clinical effects of a controlled trial of methylphenidate on adolescents with Attention Deficit Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 29, 702–709.PubMedCrossRefGoogle Scholar
  25. Leckman, J. F., & Ort, S. (1986). Rebound phenomena in Tourette’s Syndrome after abrupt withdrawal of Clonidine. Archives of General Psychiatry, 43, 1168–1176.PubMedCrossRefGoogle Scholar
  26. Mikkelsen, E. J., Detlor, J., & Cohen, D. J. (1981). School avoidance and social phobia triggered by haloperidol in patients with Tourette’s disorder. American Journal of Psychiatry, 138, 1572–1576.PubMedGoogle Scholar
  27. Munetz, M. R., & Benjamin, S. (1988). How to examine patients using the Abnormal Involuntary Movement Scale. Hospital and Community Psychiatry, 39, 1172–1177.PubMedGoogle Scholar
  28. Pelham, W. E. (1983). The effects of psychostimulants on academic achievement in hyperactive and learning-disabled children. Thalamus, 3, 1–47.Google Scholar
  29. Pelham, W. E., Sturges, J., Hoza, J., Schmidt, G., Bijlsma, J. J., Milich, R., & Moorer, S. (1987). Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics, 80, 491–501.PubMedGoogle Scholar
  30. Pelham, W. E., Greenslade, K. E., Vodde-Hamilton, M., Murphy, D. A., Greenstein, J. J., Gnagy, E. M., Guthrie, K. J., Hoover, M. D., & Dahl, R. E. (1990). Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics, 86, 226–237.PubMedGoogle Scholar
  31. Pfefferbaum, B., Overall, J. E., Boren, H. A., Frankel, L. S., Sullivan, M. P., & Johnson, K. (1987). Alprazolam in the treatment of anticipatory and acute situational anxiety in children with cancer. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 532–535.PubMedCrossRefGoogle Scholar
  32. Preskorn, S. H., Weller, E. B., Hughes, C. W., & Weller, R. A. (1988). Relationship of plasma imipramine levels to CNS toxicity in children. American Journal of Psychiatry, 145, 897.PubMedGoogle Scholar
  33. Puig-Antich, J., Ryan, N. D., & Rabinovich, H. (1985). Affective disorders in childhood and adolescence. In J. M. Wiener (Ed.), Diagnosis and psychopharmacology of childhood and adolescent disorders (pp. 151–178). New York: John Wiley & Sons.Google Scholar
  34. Realmuto, G. M., August, G. J., & Garfinkel, B. D. (1989). Clinical effect of buspirone in autistic children. Journal of Clinical Psychopharmacology, 9, 122–125.PubMedCrossRefGoogle Scholar
  35. Rew, D. A., & Rundle, J. S. (1989). Assessment of the safety of regular DDAVP therapy in primary nocturnal enuresis. British Journal of Urology, 63, 352–353.PubMedCrossRefGoogle Scholar
  36. Riddle, M. A., Hardin, M. T., King, R., Scahill, L., & Woolston, J. L. (1990). Fluoxetine treatment of children and adolescents with Tourette’s and obsessive compulsive disorders: Preliminary clinical experience. Journal of the American Academy of Child and Adolescent Psychiatry, 29, 45–48.PubMedCrossRefGoogle Scholar
  37. Riddle, M. A., Nelson, J. C., Kleinman, C. S., Rasmusson, A., Leckman, J. E., King, R. A., & Cohen, D. J. (1991). Sudden death in children receiving Norpramin: A review of three reported cases and commentary. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 104–108.PubMedCrossRefGoogle Scholar
  38. Safer, D. (1991). Effect of the media on stimulant treatment of ADHD. Paper presented at the annual meeting of the American Academy of Child and Adolescent Psychiatry.Google Scholar
  39. Safer, D. J., & Krager, J. M. (1988). A survey of medication treatment for hyperactive/inattentive students. Journal of the American Medical Association, 260, 2256–2258.PubMedCrossRefGoogle Scholar
  40. Schroeder, J. S., Mullin, A. V., Elliott, G. R., Steiner, H., Nichols, M., Gordon, A., & Paulos, M. (1989). Cardiovascular effects of desipramine in children. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 376–379.PubMedCrossRefGoogle Scholar
  41. Simeon, J. G., & Ferguson, H. B. (1985). Recent developments in the use of antidepressant and anxiolytic medications. Psychiatric Clinics of North America, 8, 893–907.PubMedGoogle Scholar
  42. Simeon, J. G., Ferguson, H. B., Knott, V., Roberts, N., Gauthier, B., Dubois, C., & Wiggins, S. (1992). Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 29–33.PubMedCrossRefGoogle Scholar
  43. Swedo, S. E., Leonard, H. L., Rapoport, J. L., Lenane, M. C., Goldberger, E. L., & Cheslow, D. L. (1989). A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine, 321, 497–501.PubMedCrossRefGoogle Scholar
  44. Tannock, R. (1991). Effects of comorbid anxiety disorder on stimulant response in children with Attention-deficit Hyperactivity Disorder (ADHD). Abstracts of Annual Meeting, American Academy of Child and Adolescent Psychiatry, p. 56.Google Scholar
  45. Towbin, K. E., Riddle, M. A., Leckman, J. F., Bruun, R. D., & Cohen, D. J. (1988). The clinical case of individuals with Tourette’s Syndrome. In D. J. Cohen, R. D. Bruun, & J. F. Leckman (Eds.), Tourette’s syndrome and tic disorders: Clinical understanding and treatment (pp. 329–352). New York: John Wiley & Sons.Google Scholar
  46. Warady, B. A., Alon, U., & Hellerstein, S. (1991). Primary nocturnal enuresis: Current concepts about an old problem. Pediatric Annals, 20, 246–255.PubMedGoogle Scholar
  47. Weiler, E. B., Weiler, R. A., & Fristad, M. A. (1986). Lithium dosage guide for prepubertal children: A preliminary report. Journal of the American Academy of Child and Adolescent Psychiatry, 25, 92–95.CrossRefGoogle Scholar
  48. Whalen, C. K., & Henker, B. (1991). Social impact of stimulant treatment for hyperactive children. Journal of Learning Disabilities, 24, 231–241.PubMedCrossRefGoogle Scholar
  49. Williams, D. T., Mehl, R., Yudofsky, S., Adams, D., & Roseman, B. (1982). The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. Journal of the American Academy of Child and Adolescent Psychiatry, 21, 129–135.CrossRefGoogle Scholar
  50. Yudofsky, S. C., Silver, J. M., & Schneider, S. E. (1987). Pharmacologic treatment of aggression. Psychiatric Annals, 17, 397–407.Google Scholar

Copyright information

© Plenum Press, New York 1994

Authors and Affiliations

  • Mina K. Dulcan
    • 1
  1. 1.Department of Child Psychiatry, Children’s Memorial Hospital, Division of Child and Adolescent PsychiatryNorthwestern University School of MedicineChicagoUSA

Personalised recommendations